Companies
US hospitals and clinics are losing $125B every year due to delayed and inaccurate medical coding. Arintra is solving this problem by automating medical coding using AI and clinical NLP. Arintra converts a patient chart instantly into insurance claims with 96% accurate medical codes and zero human intervention. Arintra has processed more than 1.63 million claims this year across its 20+ provider clients that includes health systems and large physician groups. Through automation of these charts, Arintra has reduced undercoding by 11% and coding-related claim denials by 43%. Arintra is headquartered in Austin, Texas. Arintra is bi-directionally integrated with leading EHRs including Epic, Cerner, etc. to process patient charts directly from the EHR to create a direct-to-billing claim. This direct-to-billing claim includes precise E/M levels, CPT, ICD-10, HCC, HCPCS codes with appropriate modifiers and units. Both founders have PhDs in AI, significant ML and NLP experience, 60+ patents and publications, and a combined 20+ years of experience working at B2B companies and startups in Silicon Valley.
Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.
Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. Asher Bio is backed by Third Rock Ventures and is located in South San Francisco.
At Athelas, powered by Commure, our mission is to simplify healthcare. We have bold ambitions to reimagine the healthcare experience, setting a new standard for how care is delivered and experienced across the industry. Our growing suite of AI solutions spans ambient AI clinical documentation, provider copilots, autonomous coding, revenue cycle management and more — all designed for providers & administrators to focus on what matters most: providing care. Healthcare is a $4.5 trillion industry with more than $500 billion spent annually on administrative costs, and Athelas is at the heart of transforming it. We power over 500,000 clinicians across hundreds of care sites nationwide – more than $10 billion flows through our systems and we support over 100 million patient interactions. With new product launches on the horizon, expansion into additional care segments, and a bold vision to tackle healthcare's most pressing challenges, our ambition is to move from upstart innovator to the industry standard over the next few years. Healthcare's moment for AI-powered transformation is here, and we're building the technology to power it. Come join us in shaping the future of healthcare.
We build AI-powered compliance software for behavioral health organizations. Our system keeps them continuously audit-ready, reduces documentation costs, and protects revenue by automating the compliance work clinicians hate, freeing them to focus on care.
If we've learned anything in the last few years it's that spending time with our friends and family is essential to our well-being and happiness. Unfortunately, loud and noisy places like weddings and family gatherings hinder human connection, especially for the hearing impaired. In fact, the biggest unmet need in the entire hearing healthcare industry is hearing in noisy places. AudioFocus helps patients hear in these environments by only enhancing voices nearby the patients and ignoring ones farther away. We do this using acoustics informed machine learning and custom microphone array design. Our goal is to increase the adoption rate of 37M US adults with hearing loss, only 8M use hearing aids today. Founded by Auditory Neuroscientist & AI expert and a Hearing Aid hardware design expert.
Auricle is a medical device company building a breakthrough neurostimulation implant to restore hearing in millions of patients who no longer benefit from hearing aids, get less than 60% on a word recognition test, but aren't prepared to make the jump to a cochlear implant. Our approach preserves remaining natural hearing through a reversible and less invasive surgery, addressing the key concerns that hold most patients back from getting a cochlear implant (currently the only treatment option for these patients). The company spun out of Stanford Biodesign having completed two acute human clinical studies demonstrating the approach will work. The team is now focused on developing their full implant system for their first clinical trial. Auricle addresses a currently unserved profile of hearing loss that affects a growing population of 3.5 million patients in the US and represents an immediately accessible $1.2B market opportunity with existing reimbursement.
𝐖𝐡𝐲 𝐰𝐞 𝐛𝐮𝐢𝐥𝐭 𝐭𝐡𝐢𝐬: I (Angel) have had three knee surgeries since my mid-teens and was billed more than $250K for care that should have cost a fraction of that. Fighting those inflated charges was so painful that we set out to build a consumer-facing AI agent to do it for others. In less than five months, we helped sixty patients erase or reduce over $300K from their medical bills. This inspired us to fix the problem farther upstream: stopping bad payments before the patient ever sees a bill. So we launched payment integrity, machine-learning models that audit every medical claim for self-insured employers and health plans in real time. 𝐓𝐡𝐞 𝐏𝐫𝐨𝐛𝐥𝐞𝐦: • Self-insured employers waste $60 B+ each year on claims that never should have been paid. Healthcare is the 2nd largest company expense after payroll. • Manual audits are slow and partial: Reviewers focus only on high-dollar claims, letting millions more slip through unnoticed. • Existing audit software is static: Decades-old rule engines can’t keep pace with evolving codes, contracts, or billing tactics. • Incentives are misaligned: Third-party administrators are paid to process claims, not to police them, so accuracy checks are minimal. 𝐎𝐮𝐫 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧: Our models audit medical claims before and after payments have been issued. We catch nuanced billing, coding, and contract errors to save 3-7% on annual claims spend. We work with self-insured employers and health plans. 𝐀𝐛𝐨𝐮𝐭 𝐔𝐬: Angel Onuoha (CEO) and Ahmad Shehu (CTO) have worked together for 4 years. Before Avelis Health they built Zuvy, a Lagos-based fintech company that provided invoice factoring to small businesses. Zuvy was acquired by The BAS Group in 2025.
Employee benefits - the second-largest cost center for employers - are broken. Confusing and costly for employees and companies, and shockingly manual for brokers. Legacy systems force people to sift through millions of lines of data across claims, utilization, and regulations. This is a $1.9T market stuck on manual - Avenir AI automates it. We built AI agents that deliver immediate savings and smart optimization across plans, vendors, and workflows. This level of intelligence and speed was not possible before. We started Avenir a few months ago and have already signed Fortune 500s and top-5 brokers - with $0 in marketing spend. A big problem needs the best team. We assembled a world-class, AI-native team from MIT, Apple, and Microsoft - and our traction shows it’s working. Excited to help disrupt a $1.9T legacy industry? Email me: maria@avenir.com.ai
Axle Health provides scheduling and workforce management software for home healthcare providers. The Axle platform includes a mobile app for clinicians, an operations dashboard for office teams, proprietary logistics algorithms to optimize scheduling, and a patient engagement and booking solution. Axle is integrated with a wide range of EMRs, and the entire Axle product can be customized and accessed modularly via API. Some of the biggest home health care providers in the country use Axle’s software to improve the utilization of their clinical teams, and automate the operational burden of scheduling and dispatching.
BBy's condensing device turns milk into a fine powder that spares the biome leaving it biologically and immunologically active. This allows hospitals to stop wasting precious nursing time defrosting milk for hours and milk wastage from discarding rules. Simply weigh the powder, add water, shake and serve. No more freezing, no more defrosting, only patient care. NICUs are time sensitive wards in the hospital, time is everything and yet nurses today continue to prepare frozen milk for infants in what's known as the milk shift. A shift where the nurse spends the day defrosting milk for the next shift of nurses. Our tech is now fully peer reviewed and published, yielding safe and reliable results in over 20 hospitals in the New York Tri-State. The company is headed by Vansh Langer MD, a physician (Windsor University, University of Chicago) and Blanca Aguilar Uscanga PhD, a Bioengineering/Food Science PhD (University of Guadalajara /Centro Universitario de Ciencias Exactas e Ingenierías (CUCEI)) team that has over 50 published works in the field between them and are experts in the science of infant nutrition. Vansh saw the immense need for a time critical solution in the NICU and helped solve the puzzle with Dra. Blanca and her team and decided to work together to: Nurture the Future.
Our mission -To ensure current and future generations have access to clean soil, water & air. -To protect and restore earth's beautiful and diverse ecosystems. -To undo the harm of industrial activity on the planet and ensure future industrial activities are more sustainable. Our research -We develop new bio-based solutions that break down and remove toxic chemicals from the environment. We also develop bioreactor based solutions which remove toxins from industrial production pipelines, ensuring contaminants are never released into the environment. -To do this, we've partnered with Nature. Specifically, we have harnessed the power of one of Nature's smallest but most powerful technologies: enzymes. Enzymes are everywhere. They break down the food in your stomach, remove dirt from your clothes, and make our beer. At BluumBio, we look for enzymes found in bacteria, algae, plants and other living organisms that naturally degrade toxic chemicals. We then make these enzymes work better in the lab and come up with develop new applications for these technologies.
Gain muscle and shed fat with a digital twin of your body. BODYSIM is an app-based simulation of your body and its potential that recommends nutrition and exercise to meet your goals. Use BODYSIM to (1) Assemble your data from food logging, BIA weigh-ins, DEXA scans, at-home blood tests, and wearables, (2) Learn to “triangulate the truth” of your unique metabolism and physiology, and (3) Adjust your nutrition and exercise plans by simulating what will happen to your body. One founder put on 45 lbs muscle, and another put on 25 lbs of muscle while losing 50 lbs of fat. Our alpha testers lost an average of 12.6 pounds in 3 months. Our core technology distills messy academic literature into simulations. Before turning to our own fitness journeys, we successfully deployed sophisticated enterprise models of plant-soil-atmosphere, consumer behavior and battery electrochemistry. With BODYSIM we built a science-based simulation of macronutrient balance and muscle hypertrophy. It includes cell turnover, oxidation for energy, lipolysis of fat stores, synthesis of new muscle, glycogen resynthesis, GI latency, and even ketones. Get jacked at BODYSIM.com
The main document in a clinical trial is the study protocol. At large companies, floors of people use the protocol to create the study data collection forms, clinical database design, error checks, analysis code, and data transformation mappings. We use AI to automate the process of creating everything from the protocol, saving not only spend on headcount but also months of time which can translate to up to $27M in direct costs + lost revenue saved for a single phase 3 trial.
4 Billion radiology scans are generated every year, but unfortunately, 1 in 5 reports are wrong and 35% of the studies are delayed. It can be primarily attributed to access and efficiency. BeWell is building the platform for access and efficiency
Bemlo is an AI-driven workforce management platform, specifically tailored for the healthcare and social care sectors, with automated scheduling as its cornerstone. The system generates optimal schedules that balance care demands with employee preferences, freeing up valuable time for patient care, enhancing workplace satisfaction, and promoting more efficient collaboration within organizations.
Bikanta is introducing revolutionary nanodiamond-based technology to push the boundaries of current medical imaging and diagnostics, allowing researchers to answer questions and medics to detect diseases that they currently cannot. A nanodiamond is forever. They are brightly fluorescent, infinitely stable, non-toxic, functionalizable and can be used for background-free optical imaging. Early results have improved the signal by as much as 100-fold over conventional fluorescence imaging techniques. Bikanta’s vision is to redefine the boundaries of medical diagnostics by delivering cutting-edge imaging probes and background-free optical imaging.
BillionToOne has developed a DNA molecular counter that increases the cell-free DNA diagnostics resolution by over 1,000 fold, which unlocks transformative improvements in prenatal screening and liquid biopsy for cancers. Unity Screen, BillionToOne's commercially available non-invasive prenatal test (NIPT), is the only NIPT that can assess fetal risk for both recessive conditions and aneuploidies from maternal blood. UNITY Screen continues to grow exponentially and is on its path to becoming the next standard-of-care, with an increasing number of publications showing its accuracy and advantages over other screening methods. We have also recently used our molecular counting technology to develop liquid biopsy tests, which have the potential to completely transform oncology care.
Finding new cures requires seeing what and where the abnormal molecules are in a diseased tissue, but current tools see less than 1% of those molecules. Biocartesian combines microscopy and new chemistries to see 50X more, offering unprecedented insights into disease biology and new therapies.